var data={"title":"Teriparatide (recombinant human parathyroid hormone [1-34]): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Teriparatide (recombinant human parathyroid hormone [1-34]): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7024?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=teriparatide-recombinant-human-parathyroid-hormone-1-34-patient-drug-information\" class=\"drug drug_patient\">see &quot;Teriparatide (recombinant human parathyroid hormone [1-34]): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709064\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Potential risk of osteosarcoma:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">In male and female rats, teriparatide caused an increase in the incidence of osteosarcoma (a malignant bone tumor) that was dependent on dose and treatment duration. The effect was observed at systemic exposures to teriparatide ranging from 3 to 60 times the exposure in humans given a 20 mcg dose. Because of the uncertain relevance of the rat osteosarcoma finding to humans, prescribe teriparatide only to patients for whom the potential benefits are considered to outweigh the potential risk. Teriparatide should not be prescribed for patients who are at increased baseline risk for osteosarcoma (eg, those with Paget disease of bone or unexplained elevations of alkaline phosphatase, pediatric and young adult patients with open epiphyses, or patients with prior external beam or implant radiation therapy involving the skeleton).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225837\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Forteo</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F855044\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Forteo</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225853\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Parathyroid Hormone Analog</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225839\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">\n      <b>Osteoporosis (men, postmenopausal women, glucocorticoid induced): </b>SubQ: 20 mcg once daily; <b>Note:</b> Initial administration should occur under circumstances in which the patient may sit or lie down, in the event of orthostasis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3062230\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225840\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary. Use in severe renal impairment is contraindicated in the Canadian labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22803240\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There is no dosage adjustment provided in the manufacturer&rsquo;s labeling (has not been studied). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225815\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Forteo: 600 mcg/2.4 mL (2.4 mL) [contains metacresol]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225800\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12807316\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, solution:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Forteo: 250 mcg/mL (3 mL) [delivers teriparatide 20 mcg/dose]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874998\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088604.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/9+evs591MjKrfB30zg8bRlDCZZKB1WI0BxY6WS9d1ayQ==&amp;TOPIC_ID=10178\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088604.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225818\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">SubQ: Inject subcutaneously into the thigh or abdominal wall. Administer without regard to meals or time of day. May administer dose immediately following removal from the refrigerator. Initial administration should occur under circumstances in which the patient may sit or lie down, in the event of orthostasis. Each teriparatide delivery device can be used for up to 28 days after the first injection. <b>Note:</b> The 3 mL prefilled pen (Canadian availability; not available in US) must be primed prior to each dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225817\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Glucocorticoid-induced osteoporosis:</b> Treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to prednisone 5 mg or more) at high risk for fracture.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteoporosis in men:</b> To increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteoporosis in postmenopausal women:</b> Treatment of postmenopausal women with osteoporosis who are at high risk for fracture.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15255018\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Forteo may be confused with Forfivo XL</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225806\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Endocrine &amp; metabolic: Hypercalcemia (transient increases noted 4 to 6 hours postdose [women 11%; men 6%]) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Orthostatic hypotension (5%; transient), angina pectoris (3%), syncope (3%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Dizziness (8%), headache (8%), insomnia (5%), anxiety (4%), depression (4%), vertigo (4%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Hyperuricemia (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Nausea (9% to 14%), gastritis (7%), dyspepsia (5%), vomiting (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Immunologic: Antibody development (3% of women in long-term treatment; hypersensitivity reactions or decreased efficacy were not associated in preclinical trials)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infection: Herpes zoster (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia (10%), weakness (9%), leg cramps (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Rhinitis (10%), pharyngitis (6%), dyspnea (4% to 6%), pneumonia (3% to 6%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing and/or case reports: Anaphylaxis, angioedema, chest pain, dyspnea (acute), facial edema, hypercalcemia (&gt;13 mg/dL), hypersensitivity reaction, injection site reactions (bruising, pain, swelling), mouth edema, muscle spasm, osteosarcoma, urticaria </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225821\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to teriparatide or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Preexisting hypercalcemia; severe renal impairment; metabolic bone diseases other than primary osteoporosis (including hyperparathyroidism and Paget&rsquo;s disease of the bone); unexplained elevations of alkaline phosphatase; prior external beam or implant radiation therapy involving the skeleton; bone metastases or history of skeletal malignancies; pregnancy; breast-feeding mothers; pediatric patients or young adults with open epiphysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225804\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Orthostatic hypotension: May cause orthostatic hypotension. Transient orthostatic hypotension usually occurs within 4 hours of dosing and within the first several doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Osteosarcoma: [US Boxed Warning]: In animal studies, teriparatide has been associated with an increase in osteosarcoma; risk was dependent on both dose and duration. Avoid use in patients with an increased risk of osteosarcoma (including Paget disease, prior radiation, unexplained elevation of alkaline phosphatase, prior external beam or implant radiation therapy involving the skeleton, or in patients with open epiphyses). Do not use in patients with bone metastases, a history of skeletal metastases, hyperparathyroidism, or preexisting hypercalcemia. Not for use in patients with metabolic bone disease other than osteoporosis. A voluntary patient registry has been established to collect information regarding osteosarcoma; patients are encouraged to enroll. Registry information may be obtained at www.forteoregistry.rti.org or by calling 866-382-6813.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use in severe renal impairment is contraindicated in the Canadian labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Urolithiasis: Use with caution in patients with active or recent urolithiasis because of risk of exacerbation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Multiple-dose injection pens: According to the Centers for Disease Control and Prevention (CDC), pen-shaped injection devices should never be used for more than one person (even when the needle is changed) because of the risk of infection. The injection device should be clearly labeled with individual patient information to ensure that the correct pen is used (CDC, 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Use of teriparatide for longer than 2 years is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Glucocorticoid-induced osteoporosis: For use in men and women at high risk of fracture, which is defined as a history of osteoporotic fracture or multiple risk factors for fracture. May also be used in patients who have failed or are intolerant to other available osteoporosis therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Osteoporosis in men: For use in men at high risk for fracture, which is defined as a history of osteoporotic fracture or multiple risk factors for fracture. May also be used in men who have failed or are intolerant to previous osteoporosis therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Postmenopausal osteoporosis: For use in women at high risk for fracture, which is defined as a history of osteoporotic fracture or multiple risk factors for fracture. May also be used in women who have failed or are intolerant of previous osteoporosis therapy. In postmenopausal women with osteoporosis, teriparatide reduces the risk of vertebral and nonvertebral fractures.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300117\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6223234\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10178&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225810\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225825\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal studies; the effect on human fetal development has not been studied. Teriparatide is not indicated for use in pregnant or premenopausal women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225826\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if teriparatide is excreted in breast milk. According to the manufacturer, the decision to discontinue teriparatide or discontinue breast-feeding should take into account the exposure to the infant and the benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21303675\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Ensure adequate calcium and vitamin D intake; if dietary intake is inadequate, dietary supplementation is recommended. Women and men should consume:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Calcium: 1,000 mg/day (men: 50 to 70 years) <b>or</b> 1,200 mg/day (women &ge;51 years and men &ge;71 years) (IOM, 2011; NOF [Cosman 2014])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin D: 800 to 1,000 int. units/day (men and women &ge;50 years) (NOF [Cosman 2014]). Recommended Dietary Allowance (RDA): 600 int. units/day (men and women &le;70 years) <b>or</b> 800 int. units/day (men and women &ge;71 years) (IOM, 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225812\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Orthostatic hypotension; urinary calcium (patients with suspected active urolithiasis or preexisting hypercalciuria); bone mineral density (BMD) should be evaluated 1 to 2 years  after initiating therapy and every 2 years thereafter (NOF [Cosman 2014]); annual measurements of height and weight, assessment of chronic back pain; serum calcium and 25(OH)D; consider measuring biochemical markers of bone turnover</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21303674\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium (total): Adults: 9.0 to 11.0 mg/dL (2.05 to 2.54 mmol/L), may slightly decrease with aging</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphorus: 2.5 to 4.5 mg/dL (0.81 to 1.45 mmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin D: There is no clear consensus on a reference range for total serum 25(OH)D concentrations or the validity of this level as it relates clinically to bone health. In addition, there is significant variability in the reporting of serum 25(OH)D levels as a result of different assay types in use; however, the following ranges have been suggested:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults (IOM, 2011): Sufficient levels in practically all persons: &ge;20 ng/mL (50 nmol/L); concern for risk of toxicity: &gt;50 ng/mL (125 nmol/L)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Osteoporosis patients (NOF [Cosman 2014]): Recommended level to reach and maintain: ~30 ng/mL (75 nmol/L) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225803\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Teriparatide is a recombinant formulation of endogenous parathyroid hormone (PTH), containing a 34-amino-acid sequence which is identical to the N-terminal portion of this hormone. The pharmacologic activity of teriparatide, which is similar to the physiologic activity of PTH,  includes stimulating osteoblast function, increasing gastrointestinal calcium absorption, and increasing renal tubular reabsorption of calcium. Treatment with teriparatide results in increased bone mineral density, bone mass, and strength. In postmenopausal women, teriparatide has been shown to decrease osteoporosis-related fractures.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225820\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: ~0.12 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic (nonspecific proteolysis) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: 95% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: IV: 5 minutes; SubQ: ~1 hour </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: ~30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (as metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225824\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Forteo Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mcg/2.4 mL (2.4 mL): $3,953.64</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F225827\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Forsteo (AT, BE, BG, CH, CN, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, HU, IE, IS, IT, KR, LT, LU, LV, MT, NL, NO, PL, PT, RO, RU, SE, SI, SK, TR);</li>\n      <li>Forteo (AE, AR, AU, BB, BH, BR, CL, CO, CR, DO, GT, HK, HR, JP, KW, LB, LK, MX, MY, NZ, PA, PE, PH, PY, QA, SA, SG, SV, TH, TW, VE);</li>\n      <li>Human PTH (JP);</li>\n      <li>Mega PTH (TH);</li>\n      <li>Teribone (JP, KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Body JJ, Gaich GA, Scheele WH, et al, &ldquo;A Randomized Double-blind Trial to Compare the Efficacy of Teriparatide [Recombinant Human Parathyroid Hormone (1-34)] With Alendronate in Postmenopausal Women With Osteoporosis,&rdquo; <i>J Clin Endocrinol Metab</i>, 2002, 87(10):4528-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/teriparatide-recombinant-human-parathyroid-hormone-1-34-drug-information/abstract-text/12364430/pubmed\" target=\"_blank\" id=\"12364430\">12364430</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). CDC clinical reminder: insulin pens must never be used for more than one person. Centers for Disease Control and Prevention Web site. <a href=\"http://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html\" target=\"_blank\">http://www.cdc.gov/injectionsafety/clinical-reminders/insulin-pens.html</a>. Updated January 5, 2012. Accessed January 9, 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's Guide to Prevention and Treatment of Osteoporosis. <i>Osteoporos Int</i>. 2014;25(10):2359-2381. doi: 10.1007/s00198-014-2794-2.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Forteo (teriparatide) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    IOM (Institute of Medicine), <i>Dietary Reference Intakes for Calcium and Vitamin D,</i> Washington, DC: The National Academies Press, 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neer RM, Arnaud CD, Zanchetta JR, et al, &ldquo;Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women With Osteoporosis,&rdquo; <i>N Engl J Med</i>, 2001, 344(19):1434-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/teriparatide-recombinant-human-parathyroid-hormone-1-34-drug-information/abstract-text/11346808/pubmed\" target=\"_blank\" id=\"11346808\">11346808</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reeve, J, &ldquo;Recombinant Human Parathyroid Hormone,&rdquo; <i>BMJ</i>, 2002, 324(7335):435-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/teriparatide-recombinant-human-parathyroid-hormone-1-34-drug-information/abstract-text/11859030/pubmed\" target=\"_blank\" id=\"11859030\">11859030</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Saag KG, Shane E, Boonen S, et al, &ldquo;Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis,&rdquo; <i>N Engl J Med</i>, 2007, 357(20):2028-39.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/teriparatide-recombinant-human-parathyroid-hormone-1-34-drug-information/abstract-text/18003959/pubmed\" target=\"_blank\" id=\"18003959\">18003959</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10178 Version 99.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709064\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F225837\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F855044\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F225853\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F225839\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F3062230\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F225840\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22803240\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F225815\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F225800\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F12807316\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874998\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F225818\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F225817\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F15255018\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F225806\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F225821\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F225804\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300117\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6223234\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F225810\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F225825\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F225826\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F21303675\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F225812\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F21303674\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F225803\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F225820\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F225824\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F225827\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10178|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=teriparatide-recombinant-human-parathyroid-hormone-1-34-patient-drug-information\" class=\"drug drug_patient\">Teriparatide (recombinant human parathyroid hormone [1-34]): Patient drug information</a></li></ul></div></div>","javascript":null}